GOSSAMER BIO, INC. Repayments of Long-Term Debt
GOSSAMER BIO, INC. (GOSS) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-03-17
- GOSSAMER BIO, INC. repayments of long-term debt for the quarter ending 2025-12-31 was $0.00.
- GOSSAMER BIO, INC. repayments of long-term debt for the quarter ending 2025-09-30 was $0.00.
- GOSSAMER BIO, INC. repayments of long-term debt for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- GOSSAMER BIO, INC. repayments of long-term debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- GOSSAMER BIO, INC. repayments of long-term debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- GOSSAMER BIO, INC. repayments of long-term debt for fiscal 2024 was $12.58M, a 8.34% increase from fiscal 2023.
- GOSSAMER BIO, INC. repayments of long-term debt for fiscal 2023 was $11.61M, a 100.02% increase from fiscal 2022.
- GOSSAMER BIO, INC. repayments of long-term debt for fiscal 2022 was $5.81M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $9.68M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $9.68M derived: sum of 3 quarters · filed 2026-03-17 | $12.58M 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $9.68M derived: sum of 2 quarters · filed 2025-11-05 | $12.58M 10-Q · filed 2025-11-05 | $15.48M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $9.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $12.58M 10-Q · filed 2025-08-05 | $15.48M derived: sum of 3 quarters · filed 2026-03-17 | $18.39M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $2.90M 10-Q · filed 2025-05-15 | $5.81M derived: sum of 2 quarters · filed 2026-03-17 | $8.71M derived: sum of 3 quarters · filed 2026-03-17 | $11.61M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.81M derived: sum of 2 quarters · filed 2026-03-17 | $8.71M derived: sum of 3 quarters · filed 2026-03-17 | $11.61M 10-K · filed 2026-03-17 |
| 2023-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.81M derived: sum of 2 quarters · filed 2024-11-07 | $8.71M 10-Q · filed 2024-11-07 | $11.61M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $5.81M 10-Q · filed 2024-08-12 | $8.71M derived: sum of 3 quarters · filed 2025-03-13 | $11.61M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $2.90M 10-Q · filed 2024-05-07 | $5.81M derived: sum of 2 quarters · filed 2025-03-13 | $8.71M derived: sum of 3 quarters · filed 2025-03-13 | $8.71M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.81M derived: sum of 2 quarters · filed 2025-03-13 | $5.81M derived: sum of 3 quarters · filed 2025-03-13 | $5.81M 10-K · filed 2025-03-13 |
| 2022-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.90M derived: sum of 2 quarters · filed 2023-11-09 | $2.90M 10-Q · filed 2023-11-09 | $2.90M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 10-K · filed 2024-03-05 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |